[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598811":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":27,"locations":37,"responsibleParty":55,"collaborators":59,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":21,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":21,"enrollmentInfo":74,"targetDuration":21,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":40,"whyStopped":21,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Stony Brook University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cognitive Behavioral Therapy for Insomnia Treatment Arm","EXPERIMENTAL","Cognitive Behavioral Therapy for Insomnia (CBT-I) will be delivered through an online program, Sleep Healthy Using The Internet (SHUTi).",[13,14],"Behavioral: Cognitive Behavioral Therapy for Insomnia","Drug: PET Scan with [11C]ABP688",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"BEHAVIORAL","Cognitive Behavioral Therapy for Insomnia","Cognitive Behavioral Therapy for Insomnia (CBT-I) will be delivered through an online program, Sleep Healthy Using The Internet Sleep Healthy Using The Internet (SHUTi)",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","PET Scan with [11C]ABP688","Prior to and after completing the CBT-I protocol, participants will undergo a PET scan using tracer \\[11C\\]ABP688) to quantify hippocampal mGluR5 density.",[9],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":32},"Wendy Zhang","CONTACT","(631)-638-2053","Wendy.Zhang@stonybrookmedicine.edu",{"name":34,"role":30,"phone":35,"phoneExt":21,"email":36},"Christine DeLorenzo, PhD","(631) 638-1523","christine.delorenzo@stonybrookmedicine.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Stony Brook University: Dept of Psychiatry","RECRUITING","Stony Brook","New York","11794","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-73.14094,40.92565,{"lat":50,"lon":49},[53],{"name":34,"role":30,"phone":35,"phoneExt":21,"email":54},"Christine.DeLorenzo@stonybrookmedicine.edu",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Christine DeLorenzo","Professor of Psychiatry & Biomedical Engineering, Director (CUBIT)",[60,63],{"name":61,"class":62},"National Institutes of Health (NIH)","NIH",{"name":64,"class":62},"National Institute of Mental Health (NIMH)","100598811","phase-4-the-role-of-mglur5-in-cbt-i-100598811",false,"NCT07076342","The Role of mGluR5 in CBT-I","Mechanistic Clinical Trial Evaluating the Role of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) in the Antidepressant Mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)","Inclusion Criteria:\n\n* capacity to provide informed consent,\n* at least 18 years of age\n* good physical health and absence of significant medical conditions,\n* diagnosis of major depressive disorder (MDD) with current major depressive episode as per DSM-5 criteria\n* Montgomery-Åsberg Depression Rating Scale (MADRS) score \\> 29 (at least moderate depression),\n* uniform range of sleep latencies up to 128 minutes.\n\nExclusion Criteria:\n\n* currently taking effective antidepressants,\n* lifetime history of psychosis,\n* drug or alcohol dependence in the last 6 months or abuse in the last 2 months\n* unstable medical condition (i.e., condition not adequately stabilized for ≥ 3 months)\n* nicotine use within 1 year\n* currently on medication known to affect glutamate,\n* sleep disorders, other than insomnia, such as sleep apnea,\n* recent (within 1 year) regular night shift work (or rotating shift work) or recent (within 3 months) travel across more than one time zone, or plans for this work or travel during the study period,\n* use of medication or substances that affect sleep, for example, ingestion of more \\> 600 mg of caffeine per day,\n* PET or MRI contraindications, including pregnancy or currently breastfeeding","ALL","18 Years",{"count":75,"type":76},42,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.",[82],"Major Depressive Disorder (MDD)",[84,85,86,87],"Cognitive Behavioral Therapy","CBT-I","Cognitive Behavioral Therapy & Insomnia","Major Depressive Disorder","2026-02-12",{"date":90,"type":91},"2026-02-17","ACTUAL",{"date":93,"type":91},"2025-08-01",{"date":95,"type":76},"2030-03-31",{"name":5,"class":6},1]